Jiansheng Zhao, MD
Internal Medicine · Flushing, NYNPI 1962591750
Payments from drug & device makers
Across 195 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Novo Nordisk$681
- Merz North America, Inc.$634
- AstraZeneca$434
- Phathom Pharmaceuticals, Inc.$360
- AbbVie$311
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,477100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $1,298 |
| Novo Nordisk | 24 | $681 |
| Merz North America, Inc. | 3 | $634 |
| AstraZeneca | 24 | $434 |
| Phathom Pharmaceuticals, Inc. | 5 | $360 |
| AbbVie(2 entities) | 19 | $311 |
| Amarin Pharma, Inc. | 15 | $290 |
| Boehringer Ingelheim | 14 | $268 |
| Exact Sciences | 11 | $204 |
| GSK | 9 | $170 |
| Amgen | 2 | $149 |
| Hologic Sales And Service, LLC | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 5 | $100 |
| Bayer | 6 | $99 |
| Merck | 4 | $75 |
| Novartis | 3 | $42 |
| Viatris Specialty LLC | 2 | $41 |
| Johnson & Johnson | 2 | $30 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,488 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Combivent RespimatIpratropium/Albuterol Sulfate | 263 | $163,233 |
| JanuviaSitagliptin Phosphate | 135 | $125,010 |
| RybelsusSemaglutide | 58 | $67,516 |
| JardianceEmpagliflozin | 63 | $56,074 |
| EliquisApixaban | 58 | $55,553 |
| XareltoRivaroxaban | 65 | $47,054 |
| FarxigaDapagliflozin Propanediol | 59 | $46,692 |
| SymbicortBudesonide/Formoterol Fumarate | 108 | $40,382 |
| VemlidyTenofovir Alafenamide | 22 | $38,871 |
| VascepaIcosapent Ethyl | 77 | $38,439 |
| Diclofenac Epolamine | 95 | $33,793 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $32,596 |
| TradjentaLinagliptin | 42 | $31,918 |
| Spiriva RespimatTiotropium Bromide | 41 | $28,776 |
| MultaqDronedarone Hcl | 22 | $25,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta, Spiriva Respimat, Jentadueto Xr | $268 | $288,236420 claims |
| MerckJanuvia, Janumet, Janumet Xr | $75 | $173,306188 claims |
| AstraZenecaFarxiga, Symbicort | $434 | $87,074167 claims |
| Novo NordiskRybelsus | $681 | $67,51658 claims |
| Johnson & JohnsonXarelto | $30 | $47,05465 claims |
| GSKIncruse Ellipta, Shingrix, Breo Ellipta, Arnuity Ellipta | $170 | $40,281127 claims |
| GileadVemlidy | $1,298 | $38,87122 claims |
| AbbVieCreon | $311 | $13,99921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.